PURPOSE: To develop a nanocrystalline paclitaxel formulation with a high paclitaxel-to-stabilizer ratio which can be used for hyperthermic intraperitoneal chemotherapy (HIPEC). METHODS: Paclitaxel (PTX) nanocrystals were prepared via wet milling using Pluronic F127(®) as stabilizer. The suitability of paclitaxel nanosuspensions for HIPEC treatment was evaluated by analyzing the cytotoxicity of both stabilizer and formulation, and by determining the maximum tolerated dose (MTD) and bioavailability. The effect on tumor growth was evaluated by magnetic resonance imaging (MRI) at day 7 and 14 after HIPEC treatment in rats with peritoneal carcinomatosis of ovarian origin. RESULTS: Monodisperse nanosuspensions (±400 nm) were developed using Pluronic F127(®) as single additive. The cytotoxicity and MTD of this nanocrystalline formulation was similar compared to Taxol(®), while its bioavailability was higher. MRI data after HIPEC treatment with a PTX nanocrystalline suspension showed a significant reduction of tumor volume compared to the non-treated group. Although no significant differences on tumor volume were observed between Taxol(®) and the nanosuspension, the rats treated with the nanosuspension recovered faster following the HIPEC procedure. CONCLUSION: Nanosuspensions with a high paclitaxel-to-stabilizer ratio are of interest for the treatment of peritoneal carcinomatosis of ovarian origin via HIPEC.
PURPOSE: To develop a nanocrystalline paclitaxel formulation with a high paclitaxel-to-stabilizer ratio which can be used for hyperthermic intraperitoneal chemotherapy (HIPEC). METHODS:Paclitaxel (PTX) nanocrystals were prepared via wet milling using Pluronic F127(®) as stabilizer. The suitability of paclitaxel nanosuspensions for HIPEC treatment was evaluated by analyzing the cytotoxicity of both stabilizer and formulation, and by determining the maximum tolerated dose (MTD) and bioavailability. The effect on tumor growth was evaluated by magnetic resonance imaging (MRI) at day 7 and 14 after HIPEC treatment in rats with peritoneal carcinomatosis of ovarian origin. RESULTS: Monodisperse nanosuspensions (±400 nm) were developed using Pluronic F127(®) as single additive. The cytotoxicity and MTD of this nanocrystalline formulation was similar compared to Taxol(®), while its bioavailability was higher. MRI data after HIPEC treatment with a PTX nanocrystalline suspension showed a significant reduction of tumor volume compared to the non-treated group. Although no significant differences on tumor volume were observed between Taxol(®) and the nanosuspension, the rats treated with the nanosuspension recovered faster following the HIPEC procedure. CONCLUSION: Nanosuspensions with a high paclitaxel-to-stabilizer ratio are of interest for the treatment of peritoneal carcinomatosis of ovarian origin via HIPEC.
Authors: Yolonda L Colson; Rong Liu; Emily B Southard; Morgan D Schulz; Jacqueline E Wade; Aaron P Griset; Kimberly Ann V Zubris; Robert F Padera; Mark W Grinstaff Journal: Biomaterials Date: 2010-11-01 Impact factor: 12.479
Authors: Peng Liu; Xinyu Rong; Johanna Laru; Bert van Veen; Juha Kiesvaara; Jouni Hirvonen; Timo Laaksonen; Leena Peltonen Journal: Int J Pharm Date: 2011-03-31 Impact factor: 5.875
Authors: Ian F Tannock; Carol M Lee; Jonathon K Tunggal; David S M Cowan; Merrill J Egorin Journal: Clin Cancer Res Date: 2002-03 Impact factor: 12.531
Authors: Yoon Yeo; Taichi Ito; Evangelia Bellas; Christopher B Highley; Robert Marini; Daniel S Kohane Journal: Ann Surg Date: 2007-05 Impact factor: 12.969
Authors: Elena V Batrakova; Shu Li; Anna M Brynskikh; Amit K Sharma; Yili Li; Michael Boska; Nan Gong; R Lee Mosley; Valery Yu Alakhov; Howard E Gendelman; Alexander V Kabanov Journal: J Control Release Date: 2010-01-13 Impact factor: 9.776
Authors: Pieter Colin; Lieselotte De Smet; Chris Vervaet; Jean-Paul Remon; Wim Ceelen; Jan Van Bocxlaer; Koen Boussery; An Vermeulen Journal: Pharm Res Date: 2014-05-22 Impact factor: 4.200
Authors: Félix Gremonprez; Benedicte Descamps; Andrei Izmer; Christian Vanhove; Frank Vanhaecke; Olivier De Wever; Wim Ceelen Journal: Oncotarget Date: 2015-10-06
Authors: Maciej Nowacki; Marek Wisniewski; Karolina Werengowska-Ciecwierz; Katarzyna Roszek; Joanna Czarnecka; I Łakomska; Tomasz Kloskowski; Dominik Tyloch; Robert Debski; Katarzyna Pietkun; Marta Pokrywczynska; Dariusz Grzanka; Rafał Czajkowski; Gerard Drewa; A Jundziłł; Joseph K Agyin; Samy L Habib; Artur P Terzyk; Tomasz Drewa Journal: Oncotarget Date: 2015-09-08